Acceleron Pharma And Celgene Report New Interim Clinical Data From Phase 2 Trial Of Sotatercept In Beta-Thalassemia At 2013 American Society of Hematology Annual Meeting
Published: Dec 09, 2013
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner Celgene reported new interim data at the 55th American Society of Hematology (ASH) Annual Meeting of sotatercept in patients with beta-thalassemia.
Help employers find you! Check out all the jobs and post your resume.